Inotuzumab Ozogamicin Versus Standard Care for Acute Lymphoblastic Leukemia

BACKGROUND: Inotuzumab ozogamicin, an anti-CD22 antibody conjugated to calicheamicin, is active in acute lymphoblastic leukemia. METHODS: In this phase 3 trial, adults with relapsed/refractory acute lymphoblastic leukemia were randomized to inotuzumab ozogamicin or standard intensive chemotherapy. P...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:N Engl J Med
Autores principales: Kantarjian, Hagop M., DeAngelo, Daniel J., Stelljes, Matthias, Martinelli, Giovanni, Liedtke, Michaela, Stock, Wendy, Gökbuget, Nicola, O’Brien, Susan, Wang, Kongming, Wang, Tao, Paccagnella, M. Luisa, Sleight, Barbara, Vandendries, Erik, Advani, Anjali S.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2016
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5594743/
https://ncbi.nlm.nih.gov/pubmed/27292104
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1509277
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares